StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly effient (prasugrel) — Worldwide revenue ($M) [legacy separate disclosure] ($M)

Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization)

QuarterlyAnnual
Latest, FY2018
122
Period ended Dec 31, 2018
Change on a year earlier
-68.6%
389 in FY2017
History
10 years
Since FY2009
Sources
7
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEffient (prasugrel) — Worldwide revenue ($M) [legacy separate disclosure] ($M)Year on yearSource
FY2018Dec 31, 2018122-68.6%Form 10-K (filed 2019-02-19) ↗
FY2017Dec 31, 2017389-27.3%Form 10-K (filed 2019-02-19) ↗
FY2016Dec 31, 2016535+2.3%Form 10-K (filed 2019-02-19) ↗
FY2015Dec 31, 2015523+0.2%Form 10-K (filed 2016-02-19) ↗
FY2014Dec 31, 2014522+2.7%Form 10-K (filed 2015-02-19) ↗
FY2013Dec 31, 2013509+11.3%Form 10-K (filed 2014-02-19) ↗
FY2012Dec 31, 2012457+51.1%Form 10-K (filed 2013-02-21) ↗
FY2011Dec 31, 2011303+163.0%Form 10-K (filed 2012-02-24) ↗
FY2010Dec 31, 2010115+325.9%Form 10-K (filed 2011-02-22) ↗
FY2009Dec 31, 200927–Form 10-K (filed 2011-02-22) ↗

Breakdown

What makes up effient (prasugrel) — worldwide revenue ($m) [legacy separate disclosure]

Cite this data

StockData. (2026). Eli Lilly Effient (prasugrel) — Worldwide revenue ($M) [legacy separate disclosure] ($M), annual FY2009–FY2018 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_effient_ww

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.